Citigroup Inc Viking Therapeutics, Inc. Call Options Transaction History

Citigroup Inc

  • $153 Billion
  • Q2 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 12, 2024
BUY
$47.39 - $80.2 $729,806 - $1.24 Million
15,400 New
15,400 $816,000
Q4 2023

Feb 09, 2024
BUY
$9.24 - $19.64 $831,600 - $1.77 Million
90,000 New
90,000 $1.67 Million
Q2 2023

Aug 10, 2023
BUY
$14.84 - $24.79 $514,948 - $860,213
34,700 Added 654.72%
40,000 $648,000
Q1 2023

May 11, 2023
BUY
$8.08 - $17.33 $42,824 - $91,848
5,300 New
5,300 $88,000

Others Institutions Holding VKTX

# of Institutions
478
Shares Held
66.1M
Call Options Held
6.24M
Put Options Held
3.01M
View Full List

About Viking Therapeutics, Inc.

VKTX Quotes by TradingView
  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.28B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email